Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Eli Lilly is increasing Mounjaro's UK price by 170% to match European market levels, with the highest dose now costing £330.

The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful ...

FDA grants full approval to Papzimeos for recurrent respiratory papillomatosis (RRP): Papzimeos becomes the first and only approved therapy for adults with RRP, targeting the root cause of the disease ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Seal Rock Therapeutics joins The Michael J. Fox Foundation's LITE program to help advance research and developments in ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Oikos Fusion offers a nutrient-dense dairy drink designed to support muscle mass and digestive health during weight loss ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...